KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $447.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 63.18% year-over-year to $447.4 million; the TTM value through Dec 2025 reached $447.4 million, up 63.18%, while the annual FY2025 figure was $447.4 million, 63.18% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $447.4 million in Q4 2025 per RXRX's latest filing, roughly flat from $447.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $447.4 million in Q4 2025 to a low of $23.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $232.8 million, with a median of $201.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 676.51% in 2021, then grew 2.13% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $125.3 million in 2021, then surged by 40.04% to $175.5 million in 2022, then grew by 18.41% to $207.9 million in 2023, then skyrocketed by 31.92% to $274.2 million in 2024, then surged by 63.18% to $447.4 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Shares Outstanding (Weighted Average) are $447.4 million (Q4 2025), $447.0 million (Q3 2025), and $410.3 million (Q2 2025).